Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled “Monoclonal Antibodies Used as Reagents in Drug Manufacturing.” This guidance is intended to provide recommendations for sponsors and applicants of new drug applications (NDA’s), abbreviated new drug applications (ANDA’s), biologics license applications (BLA’s), their supplements, or investigational new drug applications (IND’s) on information that should be included in applications when monoclonal antibodies (mAb’s) are used as reagents in the manufacture of drug substances regulated by the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).
Submit written comments on agency guidances at any time.
Submit written requests for single copies of this guidance to the Drug Information Branch (HFD-210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Eugenia M. Nashed, Center for Drug Evaluation and Research (HFD-570), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1050, or Kurt A. Brorson, Center for Biologics Evaluation and Research (HFM-561), 8800 Rockville Pike, Bethesda, MD 20892-0029, 301-827-0661.End Further Info End Preamble Start Supplemental Information
FDA is announcing the availability of a guidance for industry entitled “Monoclonal Antibodies Used as Reagents in Drug Manufacturing.” This guidance focuses on the chemistry, manufacturing, and control (CMC) issues that should be addressed in NDA’s, ANDA’s, BLA’s, their supplements, or IND’s. This document is not intended to cover mAb’s used as diagnostics, radiolabeled imaging agents, or therapeutic products. In the Federal Register of June 24, 1999 (64 FR 33868), FDA announced the availability of a draft version of this guidance. The June 1999 document gave interested persons an opportunity to submit comments through September 22, 1999. All comments received during the comment period have been carefully reviewed and incorporated in this revised guidance where appropriate. As a result of public input during the comment period, the final guidance is clearer and more concise than the draft version.
This Level 1 guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115; 65 FR 56468, September 19, 2000). The guidance represents the agency's current thinking on monoclonal antibodies used as reagents in drug manufacturing. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
Interested persons may, at any time, submit written comments on the guidance to the Dockets Management Start Printed Page 17185Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at http://www.fda.gov/cder/guidance/index.htm.Start Signature
Dated: March 22, 2001.
Ann M. Witt,
Acting Associate Commissioner for Policy.
[FR Doc. 01-7680 Filed 3-28-01; 8:45 am]
BILLING CODE 4160-01-S